While previous studies have the absolute level of platelet activation / aggregation pointed on antiplatelet drugs, the role of the base level of platelet activation and the %age of inhibition of platelet aggregation in response to these therapies are largely unexplored before ADAPT-DES. The researchers assessed the impact of poor platelet response to aspirin , and overall platelet aggregation during dual antiplatelet therapy on the risk of stent thrombosis is still not fully investigated.
The question now is to confirm and understand the possible significance of these changes in other diseases.. De Almeida, de Sousa and colleagues , the results for the first time to establish a link between UPR protein misfolding protein misfolding and abnormalities in the immune response. Their work helps to understand the HH, a disease less than 1 in 200-300 individuals in the world affected, but also new questions for a number of other diseases, such as neurodegenerative diseases, like Alzheimer’s disease, prion, or Parkinson ‘s disease, and type II diabetes, and some forms of cancer , all of which known to be associated with misfolded proteins to be. Continue reading “The researchers assessed the impact of poor platelet response to aspirin.”